NCT06518408View on ClinicalTrials.gov

A Real-life Study of the Use of Cabotegravir Plus Rilpivirine Long-acting in ART-experienced Pre-treated People With HIV

Active, not recruitingOBSERVATIONAL
Enrollment

287

Participants

Timeline

Start Date

June 1, 2023

Primary Completion Date

April 30, 2026

Study Completion Date

September 30, 2027

Conditions
Human Immunodeficiency Virus
Interventions
DRUG

Cabotegravir Injectable Product

long-acting regimen dosed every 2-months

DRUG

Rilpivirine Injectable Product

long-acting regimen dosed every 2-months

Trial Locations (15)

18008

Hospital Universitario Virgen de Las Nieves, Granada

18014

Hospital Campus de la Salud, Granada

26006

Hospital San Pedro, Logroño

30003

Hospital Reina Sofía, Murcia

Unknown

Hospital Universitario Puerto Real, INIBICA,, Cadiz

Jerez de la Frontera University Hospital, Cadiz

Reina Sofía University Hospital, Córdoba

Hospital Comarcal Santa Ana de Motril, Granada

Complejo Hospitalario de Jaén,, Jaén

Hu La Princesa, Madrid

Ramon Y Cajal, Madrid

Hospital General Universitario Santa Lucía, Murcia

Hospital de Son Llàtzer, Palma de Mallorca

Hospital Universitario de Canarias, Santa Cruz de Tenerife

Hospital Clínico Universitario Lozano Blesa, Zaragoza

Sponsors

Collaborators (1)

ViiV Healthcare
All Listed Sponsors
collaborator

ViiV Healthcare

INDUSTRY

lead

University Hospital Virgen de las Nieves

OTHER

NCT06518408 - A Real-life Study of the Use of Cabotegravir Plus Rilpivirine Long-acting in ART-experienced Pre-treated People With HIV | Biotech Hunter | Biotech Hunter